Cabaletta Bio Grants Options to Four New Hires

The Philadelphia biotech awarded stock options covering 240,200 shares as recruitment compensation for newly hired non-executive employees.

Updated on Nov. 11, 2026 in Biotech

Cabaletta Bio Grants Options to Four New Hires

Cabaletta Bio Inc. granted stock options covering 240,200 shares to four newly hired non-executive employees, according to a filing tied to the Nov. 2, 2026 Nasdaq closing price. The options carry an exercise price of $1.43 per share.

Why it matters

The grants were issued as recruitment incentives under Nasdaq Listing Rule 5635(c)(4), an exemption that allows employment inducement awards without prior shareholder approval. For Philadelphia's life sciences workforce, the awards signal how biotech firms are using equity to attract new staff.

The 240,200 options carry a 10-year term and a $1.43 exercise price, with aggregate potential proceeds of about $343,486 if fully exercised. Vesting is 25% after the first anniversary, with the remaining 75% vesting in 12 equal quarterly installments over three years.

The players

Cabaletta Bio Inc. (Nasdaq: CABA)

Cabaletta Bio is a clinical-stage biotechnology company headquartered in Philadelphia, Pennsylvania, developing cell therapies for autoimmune diseases.

The details

The awards were granted to four non-executive employees under Cabaletta's 2025 Inducement Plan and applicable option agreements. Each grant vests 25% on the first anniversary of the employee's start date, with the remainder vesting quarterly over the following three years.

Timeline

  1. Nov. 2, 2026: Nasdaq closing price set as the exercise price for the options.

  2. Nov. 11, 2026: Grant of the stock options reported.

Industry Dynamics

Cabaletta's grants use the employment inducement exemption in Nasdaq Listing Rule 5635(c)(4), a common route for biotech firms to compensate new hires with equity without a shareholder vote. The approach reflects how clinical-stage companies compete for scientific talent through option packages rather than cash alone.

For job seekers in Philadelphia's biotech sector, equity-based recruitment packages like these can form a significant part of total compensation. Employees hired under such plans typically see a partial vesting cliff at one year before quarterly vesting begins.

The takeaway

Equity inducement grants show how early-stage biotechs use stock options to attract talent when cash budgets are constrained. Candidates weighing offers should compare vesting terms and exercise prices alongside base salary.

Further reading

For more on the sector, explore Philadelphia Biotech coverage.

Source note: This article includes information reported by MyChesCo.